ClearPoint Neuro stock reports 18 percent Q2 revenue growth

Published on 10/07/2026 at 00:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ClearPoint Neuro stock traded at USD 11.06 on October 6, 2026, down 3.99 percent. Q2 revenue reached USD 10.9 million, while 2026 guidance fell to USD 48-52 million.

CLPT, US18507C1036, Illustration mit AI erstellt.

ClearPoint Neuro (ISIN US18507C1036) was trading at USD 11.06 on Nasdaq on October 6, 2026 at 12:13 p.m. EDT, down 3.99 percent. The company is now being assessed against its second-quarter reset, with revenue growth competing against heavier investment and a lower full-year outlook.

Q2 revenue grows 18 percent

According to the Yahoo Finance transcript dated August 3, 2026, ClearPoint Neuro reported Q2 2026 revenue of USD 10.9 million for the three months ended June 30, 2026. That was 18 percent above USD 9.2 million in Q2 2025, giving the company a clear growth figure even as the quarter fell short of expectations.

The revenue mix was uneven. Biologics and Drug Delivery revenue declined 15 percent to USD 4.0 million, while Neurosurgery Navigation revenue reached USD 5.6 million and Capital Equipment and Software revenue rose 24 percent to USD 1.3 million, according to the same Yahoo Finance transcript.

Guidance falls to USD 48-52 million

Management cut its 2026 revenue guidance to USD 48 million to USD 52 million from USD 52 million to USD 56 million. The Yahoo Finance transcript said the shift reflects spending on clinical case support, regulatory expansion, capital equipment and the ClearPoint Advanced Laboratories facility.

The quarter also showed the cost of that strategy. ClearPoint Neuro posted diluted EPS of negative USD 0.38 and held USD 29.4 million in cash at June 30, 2026, while operating cash flow was negative USD 7.0 million. For investors, the central tradeoff is visible in the numbers: revenue grew year over year, but the company is redirecting resources toward capabilities intended to support future drug delivery programs.

Analyst targets remain higher

Stifel maintained a Buy rating while cutting its price target from USD 25 to USD 22, according to Investing.com on September 15, 2026. A September 2026 consensus listing from ToAlpha showed two analysts at Strong Buy, with an average target of USD 23.50, a low of USD 22.00 and a high of USD 25.00. The average target lies 112.5 percent above the October 6 price of USD 11.06.

CLPT trades below yearly high

ClearPoint Neuro was last at USD 11.06 on Nasdaq on October 6, 2026 at 12:13 p.m. EDT. The next market test is whether the lower guidance can coexist with the company's investment in clinical capacity, preclinical services and its broader cell and gene therapy partner network.